#China #Guangzhou #NASDAQ #IPO #POMDOCTOR

POMDOCTOR LIMITED Announces Pricing of Initial Public Offering

On October 8, 2025, POMDOCTOR LIMITED, a prominent online medical services platform in China, officially announced the pricing of its initial public offering (IPO). This strategic move is a significant milestone for the company as it aims to expand its reach and enhance its services for managing chronic diseases.

The IPO will consist of 5,000,004 American Depositary Shares (ADSs) being offered at a price of $4.00 per ADS. Each six ADSs correspond to one Class A ordinary share, valued at $0.0001 per share. Notably, these ADSs have received approval for listing on the Nasdaq Global Market, set to begin trading on the same day as the announcement under the ticker symbol “POM.”

POMDOCTOR anticipates raising approximately $20 million from this offering before accounting for underwriting discounts and related expenses. Additionally, the underwriters are given an option to acquire an extra 750,000 ADSs, adding potential to the IPO’s success. This option is exercisable for 45 days following the final prospectus date, which reflects the company's confident approach to its market entry.

The completion of the offering is expected on October 9, 2025, subject to standard closing conditions. The underwriter for this IPO is Joseph Stone Capital, LLC, which is leading the charge in securing this pivotal phase for POMDOCTOR.

A registration statement on Form F-1 has been duly filed with the U.S. Securities and Exchange Commission (SEC) (File Number 333-285771), and was approved on September 30, 2025. Essential information related to the offering can be accessed through the SEC’s website as well as directly from Joseph Stone Capital, ensuring transparency in the process.

POMDOCTOR LIMITED is recognized as a leading platform in the online medical services sector, addressing the often-overlooked area of chronic diseases. It ranks as the sixth-largest entity in China’s internet hospital market based on contracted doctors as of 2022, according to Frost & Sullivan. By concentrating on chronic disease management and pharmaceutical services, POMDOCTOR serves as a true one-stop solution. It integrates various stakeholders, including patients, doctors, pharmacies, and suppliers, to create a more efficient healthcare network.

The company’s mission emphasizes the necessity for effective treatment solutions, aiming to alleviate patient suffering and improve quality of life. POMDOCTOR strives to be the most reliable platform for medical services, thereby enhancing the overall patient experience through its models focused on efficiency and transparency in healthcare delivery.

Reflecting on the IPO’s significance, POMDOCTOR’s management acknowledged the growth potential and the critical role they envision within the healthcare ecosystem. As they prepare for this expansion phase, the company remains committed to its values and mission.

Investors are encouraged to carefully review the details in the offering prospectus, which elucidates the company’s strategies, expectations, risks, and overall financial outlook. This document is vital for understanding the full scope of what POMDOCTOR aims to achieve through its public offering.

In conclusion, POMDOCTOR LIMITED's IPO marks a transformative opportunity not just for the company but for the broader healthcare landscape in China. With a focused approach and robust backing, POMDOCTOR is set to enhance its market presence and expand its impact on chronic disease management.

For more information and updates, visit POMDOCTOR.